Compare Adaptive Biotechnologies Corp (ADPT) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $95.85. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | JNK | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Fixed Income |
52-Week High | $25.45 | $98.19 |
52-Week Low | $12.30 | $94.66 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
JNK trades at $95.875, up 0.24% with a bearish technical signal from moving averages. Dividend payments of $0.52-$0.53 are scheduled through August 2026. Recent news highlights risks from AI-related corporate debt and rising oil prices affecting bond yields.
The outlook is cautious due to credit market risks and inflation concerns. Opportunities exist for income-focused investors from dividends, but volatility from Fed policy and geopolitical tensions poses significant downside risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
